Genmab reports 45.9% response rate for FRα‑directed ADC in platinum‑resistant ovarian cancer; Lilly expands Jaypirca label

Genmab presented new data on its FRα‑targeted antibody‑drug conjugate Rina‑S in patients with platinum‑resistant ovarian cancer.

In the trial, the ADC achieved an objective response rate of 45.9%, indicating a substantial proportion of patients experienced tumor shrinkage.

The results suggest the therapy could address an unmet need in this difficult‑to‑treat population, though further studies are needed to confirm durability and safety.

In parallel news, Eli Lilly announced that its drug Jaypirca received an FDA label expansion, extending its approved use.

The brief also noted additional updates from Biogen and Gate Bioscience, but no specifics were provided.